Metraipolis › archive › dc_800aa436bd26

RV144 HIV-1 vaccination impacts post-infection antibody responses — Europe PMC PMID:33290394

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/33290394
DOI
10.1371/journal.ppat.1009101
License (as archived)
CC0-1.0
Archived
2026-11-06T17:31:59.815Z
SHA-256 of the archived text
f3636671faac64076a09c9522bd5fa1eb65b5730d15a443c8150a3f52b42ebea
Stable URL of this page
https://metraipolis.com/documento/dc_800aa436bd26

How to cite

RV144 HIV-1 vaccination impacts post-infection antibody responses — Europe PMC PMID:33290394 — Europe PMC (en), https://europepmc.org/article/MED/33290394 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_800aa436bd26 (Metraipolis archive dc_800aa436bd26, sha256 f3636671faac64076a09c9522bd5fa1eb65b5730d15a443c8150a3f52b42ebea)
BibTeX
@misc{dc800aa436bd26,
  title = {RV144 HIV-1 vaccination impacts post-infection antibody responses — Europe PMC PMID:33290394},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/33290394},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_800aa436bd26; sha256 f3636671faac64076a09c9522bd5fa1eb65b5730d15a443c8150a3f52b42ebea},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/33290394. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

The RV144 vaccine efficacy clinical trial showed a reduction in HIV-1 infections by 31%. Vaccine efficacy was associated with stronger binding antibody responses to the HIV Envelope (Env) V1V2 region, with decreased efficacy as responses wane. High levels of Ab-dependent cellular cytotoxicity (ADCC) together with low plasma levels of Env-specific IgA also correlated with decreased infection risk. We investigated whether B cell priming from RV144 vaccination impacted functional antibody responses to HIV-1 following infection. Antibody responses were assessed in 37 vaccine and 63 placebo recipients at 6, 12, and 36 months following HIV diagnosis. The magnitude, specificity, dynamics, subclass recognition and distribution of the binding antibody response following infection were different in RV144 vaccine recipients compared to placebo recipients. Vaccine recipients demonstrated increased IgG1 binding specifically to V1V2, as well as increased IgG2 and IgG4 but decreased IgG3 to HIV-1 Env. No difference in IgA binding to HIV-1 Env was detected between the vaccine and placebo recipients following infection. RV144 vaccination limited the development of broadly neutralizing antibodies post-infection, but enhanced Fc-mediated effector functions indicating B cell priming by RV144 vaccination impacted downstream antibody function. However, these functional responses were not associated with clinical markers of disease progression. These data reveal that RV144 vaccination primed B cells towards specific binding and functional antibody responses following HIV-1 infection.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PLoS pathogens, 2020 (prima pubblicazione 2020-12-08).
Identificativi: PMID 33290394 · PMCID PMC7748270 · DOI 10.1371/journal.ppat.1009101.
Pagina: https://europepmc.org/article/MED/33290394 — https://doi.org/10.1371/journal.ppat.1009101. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-06T17:24:35.334Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.